Rxivist combines preprints from bioRxiv with data from Twitter to help you find the papers being discussed in your field. Currently indexing 70,182 bioRxiv papers from 306,477 authors.
Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition
Andrew L. Hong,
Won Jun Kim,
Bryan D Kynnap,
Mihir B Doshi,
Gabriel J Sandoval,
Thomas P. Howard,
Katherine M Labella,
Catherine M Clinton,
Alanna J Church,
Brian D Crompton,
Katherine A Janeway,
Barbara Van Hare,
Paul A Clemons,
Stuart L Schreiber,
David E Root,
Prafulla C Gokhale,
Susan N Chi,
Elizabeth A Mullen,
Charles W. M. Roberts,
Keith L Ligon,
Jesse S. Boehm,
William C. Hahn
Posted 05 Dec 2018
bioRxiv DOI: 10.1101/487579 (published DOI: 10.7554/elife.44161)
Posted 05 Dec 2018
Renal medullary carcinoma (RMC) is a rare and deadly kidney cancer in patients of African descent with sickle cell trait. Through direct-to-patient outreach, we developed genomically faithful patient-derived models of RMC. Using whole genome sequencing, we identified intronic fusion events in one SMARCB1 allele with concurrent loss of the other allele, confirming that SMARCB1 loss occurs in RMC. Biochemical and functional characterization of these RMC models revealed that RMC depends on the loss of SMARCB1 for survival and functionally resemble other cancers that harbor loss of SMARCB1, such as malignant rhabdoid tumors or atypical teratoid rhabdoid tumors. We performed RNAi and CRISPR-Cas9 loss of function genetic screens and a small-molecule screen and identified UBE2C as an essential gene in SMARCB1 deficient cancers. We found that the ubiquitin-proteasome pathway was essential for the survival of SMARCB1 deficient cancers in vitro and in vivo. Genetic or pharmacologic inhibition of this pathway leads to G2/M arrest due to constitutive accumulation of cyclin B1. These observations identify a synthetic lethal relationship that may serve as a therapeutic approach for patients with SMARCB1 deficient cancers.
- Downloaded 466 times
- Download rankings, all-time:
- Site-wide: 24,421 out of 70,182
- In cancer biology: 759 out of 2,385
- Year to date:
- Site-wide: 66,253 out of 70,182
- Since beginning of last month:
- Site-wide: 33,177 out of 70,182
Downloads over time
Distribution of downloads per paper, site-wide
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!